Literature DB >> 1614415

Helicase inhibition by anthracycline anticancer agents.

N R Bachur1, F Yu, R Johnson, R Hickey, Y Wu, L Malkas.   

Abstract

Helicases are essential to both DNA replication and transcription because they separate double-stranded DNA, preparing the single strands for replication or transcription. Because the anti-cancer anthracycline antibiotics stabilize double-stranded DNA primarily by their intercalative binding, we expected the intercalated antibiotics to interfere with helicase action. We examined anthracycline antibiotic effects on SV40 large T antigen helicase activity, using a duplex DNA helicase substrate of 32P-labeled 17-mer annealed to complementary M13mp19(+) circular single-stranded DNA. The T antigen helicase activity was potently inhibited by the anthracycline antibiotics. The T antigen helicase IC50 values for the anthracycline antibiotics were as follows: nogalamycin, 2 x 10(-7) M; daunorubicin, 4 x 10(-7) M; doxorubicin, 4 x 10(-7) M; idarubicin, 1.8 x 10(-6) M; 4'-epidoxorubicin, 2 x 10(-6) M; aclacinomycin, 4 x 10(-6) M; and menogaril, 6 x 10(-6) M. Partially purified helicases from HeLa cells and murine mammary carcinoma FM3A cells also were potently inhibited by doxorubicin, with IC50 values of 4 x 10(-7) M and 9 x 10(-7) M, respectively. Because the abundance, specificities, and types of helicases vary in the cell, this site of action for anthracycline antibiotics may help explain anthracycline potency, drug specificity for DNA or RNA inhibition, and some types of cellular resistance to these drugs.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1614415

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

1.  Inhibition of unwinding and ATPase activities of pea MCM6 DNA helicase by actinomycin and nogalamycin.

Authors:  Ngoc Quang Tran; Xuan Hoi Pham; Renu Tuteja; Narendra Tuteja
Journal:  Plant Signal Behav       Date:  2011-03-01

2.  Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase.

Authors:  M T Howard; S H Neece; S W Matson; K N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

3.  Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposide.

Authors:  J Damrot; T Nübel; B Epe; W P Roos; B Kaina; G Fritz
Journal:  Br J Pharmacol       Date:  2006-11-06       Impact factor: 8.739

4.  Rapid emergence and mechanisms of resistance by U87 glioblastoma cells to doxorubicin in an in vitro tumor microfluidic ecology.

Authors:  Jeonghun Han; Yukyung Jun; So Hyun Kim; Hong-Hoa Hoang; Yeonjoo Jung; Suyeon Kim; Jaesang Kim; Robert H Austin; Sanghyuk Lee; Sungsu Park
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-22       Impact factor: 11.205

Review 5.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

6.  Genetic variants contributing to daunorubicin-induced cytotoxicity.

Authors:  R Stephanie Huang; Shiwei Duan; Emily O Kistner; Wasim K Bleibel; Shannon M Delaney; Donna L Fackenthal; Soma Das; M Eileen Dolan
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

7.  Optimizing the time of Doxil injection to increase the drug retention in transplanted murine mammary tumors.

Authors:  Shaojin You; Lian Zuo; Wei Li
Journal:  Int J Nanomedicine       Date:  2010-04-07

8.  Functions of yeast helicase Ssl2p that are essential for viability are also involved in protection from the toxicity of adriamycin.

Authors:  Takemitsu Furuchi; Tsutomu Takahashi; Shogo Tanaka; Katsushi Nitta; Akira Naganuma
Journal:  Nucleic Acids Res       Date:  2004-05-11       Impact factor: 16.971

9.  A chloroplast DNA helicase II from pea that prefers fork-like replication structures

Authors: 
Journal:  Plant Physiol       Date:  1998-11       Impact factor: 8.340

Review 10.  Anthracycline antibiotics in cancer therapy. Focus on drug resistance.

Authors:  D J Booser; G N Hortobagyi
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.